Combination therapy for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four treatments (two investigational drugs, a targeted therapy, and chemotherapy) as a first-line option for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have stomach or gastroesophageal junction cancer that is locally advanced or has spread, and has not been treated before.
- Your overall health is good (ECOG score 0-1).
- You have at least one tumor that can be measured on scans.
- Your blood counts, liver, kidney, and heart function are within acceptable limits.
- You have not had any prior treatment for this cancer, except if you finished adjuvant chemo more than 6 months ago.
- You are not pregnant or breastfeeding, and you agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study tests a new drug (Retlirafusp alfa) combined with chemotherapy against a standard immunotherapy drug with chemotherapy for people with advanced stomach cancer that has spread to the liver. It aims to see if the new combination works better as a first-line treatment.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
Hear when a new Gastric Cancer/Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.